Examining a Novel TROP-2 ADC DB-1305

DB-1305 is a novel TROP-2–targeted antibody–drug conjugate (ADC) showing early promise in pretreated metastatic TNBC, building on the pharmacologic foundation of existing TROP-2 ADCs. Phase I/II data included 26 patients with a median of two prior therapy lines, all of whom were SG-naïve. The primary endpoints were overall response rate (ORR) and safety. As DB-1305 progresses through clinical development, pharmacists and physicians must prepare for proactive toxicity monitoring, patient education, and coordination of care. Additionally, DB-1305 is being evaluated in combination with an investigational anti–PD-L1 × VEGF bispecific antibody, exploring potential synergistic activity in TNBC.